REGULATION OF ELEMENTAL IMPURITIES IN MEDICINES: IMPLEMENTATION OF ICH Q3D AND ANALYTICAL CHALLENGES
Keywords:
elemental impurities, heavy metals, pharmaceutical quality, risk assessment, toxicology, regulatory complianceAbstract
The purpose of this study is to emphasize the importance of controlling elemental impurities in pharmaceutical products to protect patient health and ensure product quality. Medicines must be as pure as possible because the presence of elemental impurities, which are traces of metals introduced during production, purification, transportation, or storage, can have toxic effects and pose significant health risks. The methodology used in this study involved a detailed review of international guidelines, published research, and analytical techniques related to detecting and regulating elemental impurities. Special focus was placed on the guideline of the International Council for Harmonization on elemental impurity control, which establishes toxicologically based limits for permitted daily exposure. This guideline promotes a scientific and risk-based approach to impurity management. The results show that adherence to Good Manufacturing Practice and thoughtful process design can reduce, but not completely eliminate, elemental impurities. Modern analytical technologies such as inductively coupled plasma mass spectrometry and atomic absorption spectroscopy provide more accurate detection and quantification than classical heavy metal tests. The conclusions highlight that understanding the potential sources of contamination — including raw materials, equipment, water, and packaging — is essential to maintaining safe impurity levels. It is recommended that pharmaceutical manufacturers develop and apply thorough risk assessment strategies throughout production. Continuous monitoring of impurity levels and strict compliance with international standards are crucial for ensuring safety. Additional data from reviewed literature confirm that a systematic, science-driven approach significantly improves impurity control. Such strategies enhance both the reliability of pharmaceutical products and the safety of patients. Ultimately, effective control of elemental impurities represents a cornerstone of modern pharmaceutical quality assurance
References
Committee for Medicinal Products for Human Use (CHMP). (2019). Guideline for elemental impurities (EMA/CHMP/QWP/115498/2017). European Medicines Agency. https://www.ema.europa.eu
European Directorate for the Quality of Medicines & HealthCare (EDQM). (2021). Implementation of policy on elemental impurities in the certification procedure (PA/PH/CEP (16) 23, 2R). https://www.edqm.eu
European Medicines Agency (EMA). (2008). Guideline on the specification limits for residues of metal catalysts or metal reagents (EMEA/CHMP/SWP/4446/2000). https://www.ema.europa.eu
European Pharmacopoeia (Ph. Eur.). (2022). Chapter 2.4.20: Determination of elemental impurities. Council of Europe.
European Pharmacopoeia. (2020). 5.20: Elemental impurities. In European Pharmacopoeia (10th ed.). Council of Europe.
Hao, Y., Yin, G., Wang, X., Fu, J., Cao, Q., Sun, Q., Zhang, G., & Feng, Z. (2024). Development and validation of analytical procedure for elemental impurities in rosuvastatin calcium tablets by ICP‐MS and microwave digestion. Journal of Analytical Methods in Chemistry, 2024(1), Article 9952318. https://doi.org/10.1155/2024/9952318
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (1999). ICH guideline Q6A: Specifications – Test procedures and acceptance criteria for new drug substances and new drug products. https://www.ich.org
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2005). ICH Q2(R1): Validation of analytical procedures: Text and methodology. https://www.ich.org
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2012). Q11: Development and manufacture of drug substances (chemical entities and biotechnological/biological entities). https://www.ich.org
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2022). ICH guideline Q3D (R2) on elemental impurities. ICH Secretariat. https://www.ich.org/page/quality-guidelines
Tvermoes, B. E., Unice, K. M., Paustenbach, D. J., Finley, B. L., Otani, J. M., & Galbraith, D. A. (2014). Effects and blood concentrations of cobalt after ingestion of 1 mg/day by human volunteers for 90 days. The American Journal of Clinical Nutrition, 99(3), 632–646. https://doi.org/10.3945/ajcn.113.071449
United States Pharmacopeia (USP). (2022). Chapter <233>: Elemental impurities—Procedures. In USP–NF. Rockville, MD: United States Pharmacopeial Convention.
United States Pharmacopeia (USP). (2022). General Chapter <232>: Elemental impurities in pharmaceutical products—Limits. In USP–NF. Rockville, MD: United States Pharmacopeial Convention.
U.S. Food and Drug Administration. (1999). Container closure systems for packaging human drugs and biologics: Guidance for industry. U.S. Department of Health and Human Services. https://www.fda.gov
U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), & Center for Biologics Evaluation and Research (CBER). (2018). Elemental impurities in drug products: Guidance for industry. U.S. Department of Health and Human Services. https://www.fda.gov
